Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis drug

This page shows the latest multiple sclerosis drug news and features for those working in and with pharma, biotech and healthcare.

Biogen triumphs over Mylan’s Tecfidera patent challenge

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling. Biogen has scored its first major success of the year, winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera.  . ... The dispute was a significant one for Biogen –

Latest news

  • Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

    BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to ... $94m. Meanwhile, Caforio is confident that

  • Cosentyx, Entresto drive topline growth for Novartis in Q4 Cosentyx, Entresto drive topline growth for Novartis in Q4

    Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m Novartis posted for the drug in Q3. ... Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer

  • Biogen under fire over $88,000 Vumerity annual price Biogen under fire over $88,000 Vumerity annual price

    Pricing pressure levelled at Tecfidera follow-up MS drug. Biogen has been criticised for the price of its next-generation multiple sclerosis drug Vulmerity, after pricing it at $88, 000 for ... patients who are stable on Tecfidera will be unwilling to to

  • Sandoz expands into Japan with €400m Aspen deal Sandoz expands into Japan with €400m Aspen deal

    Aspen’s portfolio consists of approximately 20 off-patent medicines, including anaesthetics like Xylocaine and speciality brands such as immune suppressing drug Imuran for multiple sclerosis patients.

  • Sandoz finally wins FDA approval for Neulasta biosimilar Sandoz finally wins FDA approval for Neulasta biosimilar

    The patents on the drug expired in the US in October 2015, and in Europe on August 2017, according to data from the Generics and Biosimilars Initiative (GaBi). ... This includes all biosimilars, biopharmaceutical contract manufacturing and Glatopa sales

More from news
Approximately 0 fully matching, plus 142 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The key difference between DS-8201

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee. ... The company has just secured 'Rapid Uptake' status for its multiple sclerosis drug Mavenclad via the new Accelerated Access Collaborative process

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Novartis faced similar difficulties in the UK when its multiple sclerosis drug Gilenya was declined by the National Institute for Health and Clinical Excellence (NICE) due to its comparator, Avonex, not ... High-end scenario planning capabilities will

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept). ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics